Global Epidermolytic Ichthyosis Market, By Medication (Topical Keratolytics, Topical Emollients, Retinoid and Others), Route of Administration (Topical, Oral and Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Epidermolytic ichthyosis is a type of a rare disorder which is seen to affect 1 in 100,000–300,000 infants both in males and females equally. The differential diagnosis for epidermolytic ichthyosis comprises other congenital ichthyoses, syndromic genodermatoses and the vesiculobullous and erosive disorders
Data Bridge Market Research analyses that the epidermolytic ichthyosis market was valued at USD 28 million in 2021 and is likely to reach USD 42.97 million by 2029, and is estimated to grow at a CAGR of 5.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa
|
|
Market Players Covered
|
GlaxoSmithKline plc (US), Elorac (US), Prasco Laboratories (US), SMG Pharmaceuticals (US), Lannett (US), Bausch Health Companies Inc. (Canada), Ion Labs Inc. (US), Mylan N.V. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).
|
|
Market Opportunities
|
|
Market Definition
Epidermolytic ichthyosis (EI) is a genetic skin illness characterised by blistering and subsequent reactive scaling of the skin in variable degrees. Mid-epidermal splitting and hyperkeratosis are seen in the underlying histology, which is referred to as epidermolytic hyperkeratosis (EHK). The symptoms might range from moderate blistering on friction to severe erosions or widespread warty scaling ("porcupine man"), depending on the type of the underlying mutation. Some variations of the condition include palmoplantar keratoderma (excessive callus growth on the palms and soles) and/or hair irregularities.
Epidermolytic Ichthyosis Market Dynamics
Drivers
- Rise in the cases of genetic skin disorders
The increase in the prevalence of genetic skin conditions such as superficial epidermolytic ichthyosis bullosa and desmosomal disorders such as McGrath ectodermal dysplasia-skin fragility syndrome across the globe acts as one of the major factors driving the growth of epidermolytic ichthyosis market.
- Increase in the incidence of genetic mutations
The genetic mutations are arising because of the disfunctioning in normal genes which is the main contributor of the market growth.
- Growing research and development
Rising development and the advancement in the genetic skin disorder therapeutics is further anticipated to propel the growth market growth.
Additionally, the increase in demand for effective therapies, changes in weather, development in technology and population growth positively affect the epidermolytic ichthyosis market.
Opportunities
In addition, the constant development of new treatment methods and rise in the healthcare expenditure will further provide potential opportunities for the growth of the epidermolytic ichthyosis market in the coming years.
Restraints/Challenges
On the flip side, the dearth of awareness regarding the treatment is further projected to impede the growth of the epidermolytic ichthyosis market in the timeline period. However, the less to none treatment options available might further challenge the growth of the epidermolytic ichthyosis market in the near future.
This epidermolytic ichthyosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on myeloid epidermolytic ichthyosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Epidermolytic ichthyosis affects about one in every 100,000 people. It affects both men and women in almost similar percentages. Each pregnancy has a 50% chance of transferring the faulty gene from the sick parent to the offspring. Males and females are equally at risk. A spontaneous mutation can induce epidermolytic ichthyosis in some situations.
The epidermolytic ichthyosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Epidermolytic Ichthyosis Market
Various countries' socioeconomic conditions around the world. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in medication adherence during the pandemic. However, in the post-COVID scenario, epidermolytic ichthyosis market is projected to be significantly impacted.
Global Epidermolytic Ichthyosis Market
The epidermolytic ichthyosis market is segmented on the basis of treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Medication
- Topical Keratolytics
- Topical Emollients
- Retinoid
- Others
On the basis of medication, the epidermolytic ichthyosis market is segmented into topical keratolytics, topical emollients, retinoid and others.
Route of Administration
- Topical,
- Oral
- Others
On the basis of route of administration, the epidermolytic ichthyosis market is segmented into topical, oral and others.
End User
- Hospitals
- Specialty Clinics
- Others
On the basis of end user, the epidermolytic ichthyosis market is segmented into hospitals, specialty clinics, others.
End Users
- Hospitals
- Specialty Clinics
- Others
On the basis of end users, the epidermolytic ichthyosis market is segmented into hospitals, specialty clinics and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
On the basis of distribution channel, the epidermolytic ichthyosis market is segmented into hospital pharmacy, retail pharmacy, others.
Epidermolytic Ichthyosis Market Regional Analysis/Insights
The epidermolytic ichthyosis market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-user and distribution channel as referenced above.
The countries covered in the epidermolytic ichthyosis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
Asia-Pacific dominates the epidermolytic ichthyosis market due to the rise in the incidence of genetic skin disorders. North America is projected to observe significant amount of growth in the occurrence of global players on novel technology. Moreover, the rise in the investment in research and development is further anticipated to propel the growth of the epidermolytic ichthyosis market in the region during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Epidermolytic Ichthyosis Market Share Analysis
The epidermolytic ichthyosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epidermolytic ichthyosis market.
Some of the major players operating in the epidermolytic ichthyosis market are:
- GlaxoSmithKline plc (US)
- Elorac (US), Prasco Laboratories (US)
- SMG Pharmaceuticals (US)
- Lannett (US)
- Bausch Health Companies Inc. (Canada)
- Ion Labs Inc. (US)
- Mylan N.V. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
SKU-